register

News - MedTech & Diagnostics

New Medicare subsidies for breast cancer scans

Health Industry Hub | October 3, 2019 |

From 1 November 2019, Medicare will subsidise breast cancer scans, saving women up to $1,500 per scan, and PET scans for advanced breast cancer, saving up to $1000 per scan.

In line with October Breast Cancer Awareness Month the Government has also increased their commitment to the McGrath Foundation breast cancer nurses. An additional $27.7 million will see the number of Commonwealth-funded nurses rise from 57 to 98 by 2022–23.

Breast cancer is the most common cancer among Australian women apart from non-melanoma skin cancer.

It is important women of all ages self-check their breasts, and women aged 50 to 74 years take up BreastScreen Australia’s invitation of a free screening. Many women are still not participating in the free screening program, although it could save their lives.

A customer experience mindset to deliver superior value gives healthcare service providers and suppliers a healthy edge.
Enhance visibility and amplify your brand value proposition to our 8,500+ industry professionals. Health Industry Hub offers a wealth of content in a one-stop-hub to connect and engage Pharma, MedTech and Biotech industry professionals. Contact us.

In 2019, it is estimated more than 19,300 Australian women will be diagnosed with breast cancer. More than 3,000 women are expected to die from the disease.

As a result of the huge strides made in diagnosing breast cancer early and in treatment, more than nine out of 10 women diagnosed with breast cancer in Australia will survive.

But prevention is always better than cure. Every woman can learn about these to understand her own risk. Information is available on the Cancer Australia’s website: https://breastcancerriskfactors.gov.au

The Government continues to list the latest proven treatments for breast cancer on the PBS. In May, Ibrance (palbociclib) was listed for patients with inoperable or metastatic hormone receptor positive breast cancer. Around 3,000 women each year will benefit from this decision. Without the PBS subsidy, Ibrance would cost around $55,000 for a year’s treatment.

You may also like TGA announces implant decision


Leadership & Management

David Henderson appointed Takeda Oceania Country Head

David Henderson appointed Takeda Oceania Country Head

Health Industry Hub | August 10, 2026 |

David Henderson has been appointed Country Head for Takeda Oceania, succeeding Dave Pearce, as the pharmaceutical company continues to reshape […]

More


News - Pharmaceuticals

GBMA puts medicine shortages on the table as strategic agreement talks begin

GBMA puts medicine shortages on the table as strategic agreement talks begin

Health Industry Hub | August 10, 2026 |

As the Generic and Biosimilar Medicines Association (GBMA) begins negotiations with government on the next strategic agreement, it has unveiled […]

More


News - MedTech & Diagnostics

Australia sets a new course for prostate cancer detection

Australia sets a new course for prostate cancer detection

Health Industry Hub | August 10, 2026 |

Australia has become one of the first countries in the world to adopt a modern, evidence-based framework for the early […]

More


News - Pharmaceuticals

IVF success rates climb as ART sector faces major accreditation overhaul

IVF success rates climb as ART sector faces major accreditation overhaul

Health Industry Hub | August 10, 2026 |

Australians undergoing in vitro fertilisation (IVF) are now more likely to take home a baby than they were five years […]

More


This content is copyright protected. Please subscribe to gain access.